View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 8, 2021

Dermavant raises $200m to support tapinarof launch

The revenue sale proceeds will be used towards milestone payments linked to the approval of tapinarof for psoriasis in the US.

Dermavant Sciences has signed a $160m revenue interest purchase and sale agreement for tapinarof with Marathon Asset Management, NovaQuest Capital Management and a third unnamed institutional investor in the US.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

A Roivant Sciences subsidiary, Dermavant focuses on developing and marketing treatments in immuno-dermatology areas with unmet medical needs.

Tapinarof is an investigational aryl hydrocarbon receptor modulating agent being developed by the company as a once-daily, steroid-free topical cream for treating plaque psoriasis and atopic dermatitis.

In July 2018, GlaxoSmithKline signed an agreement to divest rights to tapinarof to Dermavant following a deal valued at nearly $354m (£250m).

As per the latest revenue purchase and sale agreement, the participants bought a capped single-digit percentage revenue interest in net tapinarof sales across all dermatological therapeutic areas in the US for a total of $160m.

Dermavant will receive this funding on obtaining the US Food and Drug Administration (FDA) approval for tapinarof.

The company will use these proceeds to pay some one-time milestone payments linked to the approval and market introduction of the drug for psoriasis treatment in the US and other general corporate requirements.

In addition, Dermavant signed a $40m senior secured credit facility with the US-based undisclosed investor.

The proceeds from the loan were utilised to pay its existing secured credit facility and the remaining net funds will be used towards working capital and other corporate needs.

Earlier, the company reported positive data from a Phase III trial of tapinarof cream in adult plaque psoriasis patients and also submitted a new drug application (NDA) for the product to the FDA.

Dermavant CEO Todd Zavodnick said: “These transactions will allow Dermavant to fully fund all milestone payments associated with the approval of tapinarof for the treatment of psoriasis in the US and increase our investment in its commercial launch.

“Following the recent NDA submission for tapinarof in plaque psoriasis, we plan to initiate a Phase III trial for the drug in atopic dermatitis in the second half of the year.”

Dermavant signed an exclusive agreement to licence the development and commercial rights of tapinarof in Japan in January last year.


PR: https://www.dermavant.com/dermavant-announces-200-million-of-financing/

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology